GlassScriptPhysician profile
Luz Elena Cano
NPI 1619993698
$28,510.67
in general payments reported to CMS, 2019-2025
78 companies · $6,272 in 2025
The $6,272 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,537 · 2020: $3,307 · 2021: $3,460 · 2022: $3,332 · 2023: $3,170 · 2024: $4,433 · 2025: $6,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $53.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,821.98 |
| Education | $53.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,443.08 | 2020-2025 | Rystiggo, Briviact, Zilbrysq |
| Abbvie INC. | $2,981.08 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novartis Pharmaceuticals Corporation | $2,185.64 | 2019-2025 | |
| Medtronic USA, INC. | $1,359.95 | 2019-2020 | |
| Pfizer INC. | $1,272.25 | 2019-2025 | |
| Allergan, INC. | $1,200.11 | 2019-2022 | |
| Amgen INC. | $1,193.12 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $1,166.85 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Neurocrine Biosciences, INC. | $1,091.59 | 2019-2025 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $1,012.19 | 2019-2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $965.18 | 2019-2025 | Crexont, Rytary |
| Biogen, INC. | $956.20 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Lilly USA, LLC | $855.79 | 2019-2025 | Kisunla, Amyvid, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $694.01 | 2019-2024 | Trintellix |
| Axsome Therapeutics, INC. | $508.36 | 2024-2025 | Auvelity, Symbravo |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luz Cano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.